glp-1 and dpp4 Inhibitors vs Agonists | June 2021 | Clinical Corner DPP4 Inhibitor Mechanism of Action
Description
Patients should have thyroid function monitored during substantial weight loss, with dose adjustments based on TSH and FT4 results
GLP-1 also slows down the stomach emptying, which could lead to less glucose from the food into the bloodstream
While others battle sudden vomiting, bloating, diarrhea, or painful constipation, these symptoms usually peak during the increase in dose
These regions contain high densities of GLP-1R, allowing GLP-1 to directly exert its action onto the brain tissue
